SOT recipients can develop either primary or secondary (reactivation) CMV infection and disease. Primary in- fection occurs when a CMV-seronegative (R-) individual receives an allograft from a CMV-seropositive donor (D+) ( 23). CMV-seronegative recipients lack pre-existing CMV-speciﬁc humoral and cell-mediated immunity and,
If you want to change selection, open document below and click on "Move attachment"
- (no access) - CMV ASM.pdf, p2
|status||not read|| ||reprioritisations|
|last reprioritisation on|| ||suggested re-reading day|
|started reading on|| ||finished reading on|